FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing

In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies

Press Release - Jan 19, 2023
Selux Diagnostics

BOSTON, January 19, 2023 (Newswire.com) - Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System — a rapid antibiotic susceptibility (AST) testing platform that provides targeted therapeutic results days faster than the current standard of care. 

The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel. Selux's NGP Gram-Negative panel is currently under review by the FDA. 

"This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance. Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs. We thank all our employees, partners, and advisors who contributed to this tremendous accomplishment," said Steve Lufkin, CEO of Selux Diagnostics.

"We have been waiting for true innovation in AST technologies to deliver rapid results that are accurate according to the latest FDA guidelines and include newly approved antibiotics," said James S. Lewis II, PharmD, FIDSA, co-director of antibiotic stewardship at Oregon Health and Science University, and chair, CLSI Antimicrobial Susceptibility Testing Subcommittee. "I am enthusiastic that the Selux NGP System addresses these critical needs and will become an essential tool for directing personalized therapies for infected patients."

Experts predict that without a significant change in today's treatment options, deaths from superbugs will surpass deaths from cancer by 2050. Selux is confronting this global health crisis head-on by redefining the speed and performance of AST, the critical diagnostic test that informs personalized antibiotic therapy.

For more information on the Selux NGP System, visit www.seluxdx.com.

Acknowledgment

This platform has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); and Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.

About Selux Diagnostics 

Selux Diagnostics is transforming patient care by accelerating the selection of personalized antimicrobial therapy for all Infectious Disease patients. This advance will save lives, shorten hospital stays, and combat the growing antibiotic resistance epidemic by decreasing the overuse of broad-spectrum agents. Learn more at www.seluxdx.com.

Source: Selux Diagnostics

Share:

Tags: 510(k) cleared, AMR, antibiotic resistance, antibiotic stewardship, Antibiotic susceptibility test, AST, biotechnology, diagnostics, FDA, FDA clearance, Selux Diagnostics, superbugs

About Selux

View Website

Selux Diagnostics is focused on advancing science and technology to improve treatments for all infectious disease patients. By providing rapid AST results Selux is combatting the superbug epidemic head-on.

Selux
56 Roland Street (106)
Charlestown, MA 02129
United States
Selux Diagnostics Announces Additional $48 Million in Funding
This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
Selux - Apr 1, 2024
The Selux PBC Separator With Selux AST System Receives FDA 510(k) Clearance for Rapid Antibiotic Susceptibility Testing Direct From Positive Blood Culture
The Selux PBC Separator, part of the Next Generation Phenotyping (NGP) System, makes this the only FDA cleared, single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.
Selux - Feb 26, 2024
Selux Diagnostics Receives FDA Clearance on Their Gram-Negative Panel, Expanding the Antibiotic Menu for Its Next Generation Phenotyping System for Rapid AST
Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies.
Selux - Apr 24, 2023